6 completed, 3 unknown, 2 terminated. 11 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 11 | Completed 6, Unknown 3, Terminated 2 |
Follow pegvisomant: new trials by email Literature Review of pegvisomant trials Research Report on pegvisomant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Growth Hormone as a Model for Reversible Activation of Adipose Tissue Fibrosis Growth hormone, saline and GH receptor blockade (Pegvisomant) - Fibrosis | Not applicable | Unknown | University of Aarhus | 10 | 2021-08-01 | 2023-05-30 |
| Lipolytic Effects of GH in Human Subjects in Vivo Growth Hormone, Pegisomant - Metabolic Diseases, Growth Hormone Treatment | Not applicable | Completed | University of Aarhus | 9 | 2016-05-30 | 2020-03-26 |
| Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting Fasting, Saline, Pegvisomant - Healthy | Not applicable | Completed | University of Aarhus | 10 | 2015-07-01 | 2016-11-23 |
| Acromegaly Combination Treatment Study Pegvisomant, Octreotide LAR, Lanreotide - Acromegaly | Not applicable | Terminated | Cedars-Sinai Medical Center | 76 | 2012-03-29 | 2023-01-04 |
| Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency Pegvisomant, Regular insulin - Adults Growth Hormone Deficiency. | Not applicable | Unknown | Oregon Health and Science University | 10 | 2011-03-01 | 2013-10-24 |
| Tissue Biomarker for Pegvisomant Action Pegvisomant - Acromegaly | Not applicable | Completed | Cedars-Sinai Medical Center | 8 | 2010-11-01 | 2017-08-22 |
| The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons Somatropin, Pegvisomant - Interaction Between the GH/IGF-I System and the Immune-system | Not applicable | Unknown | Herlev Hospital | 12 | 2009-09-01 | 2009-09-01 |
| Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients Pegvisomant, Somatostatin analog (lanreotide or octreotide) - Acromegaly, Insulin Resistance | Not applicable | Completed | University of Aarhus | 18 | 2008-06-01 | 2012-01-26 |
| Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content Somatropin and pegvisomant - Metabolism, Fatty Liver | Not applicable | Completed | University of Aarhus | 10 | 2006-08-01 | 2008-08-12 |
| Growth Hormone Signaling in Vivo in Humans Saline infusion, Human Growth Hormone, Pegvisomant - Intracellular Signaling Peptides and Proteins | Not applicable | Completed | University of Aarhus | 8 | 2005-09-01 | 2007-08-07 |
| Effect of Pegvisomant on GH/IGF-I Relationship in GHD pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks, GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo), blood sampling before and after pegvisomant/placebo - Severe Adult Growth Hormone Deficiency | Not applicable | Terminated | The Christie NHS Foundation Trust | 2004-12-01 | 2007-05-03 |
Insulin Resistance (4) · Acromegaly (3) · Dwarfism, Pituitary (1) · Fasting (1) · Fatty Liver (1) · Fibrosis (1) · Glucose Intolerance (1) · Metabolic Diseases (1) · Pituitary Diseases (1)
University of Aarhus (6) · Cedars-Sinai Medical Center (2) · Herlev Hospital (1) · Oregon Health and Science University (1) · The Christie NHS Foundation Trust (1)
Denmark (7) · United States (3) · United Kingdom (1)
Shlomo Melmed, MD (2) · Lars C Gormsen, MD (1) · Louise Moller, MD (1) · Peter J Trainer, MD FRCP (1)
PMID 17492951, PMID 18460563, PMID 19820031, PMID 20731625, PMID 23785020, PMID 26496767, PMID 31668393, PMID 31724339, PMID 32754748